This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/chemspider/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/pubchem-compound/
n15http://linked.opendata.cz/ontology/sukl/drug/
n16http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01301/identifier/pubchem-substance/

Statements

Subject Item
n2:DB01301
rdf:type
n3:Drug
n3:description
A pyrrolidinylmethyl tetracycline. [PubChem]
n3:group
approved
n3:indication
Rolitetracycline is a broad-spectrum antibiotic used in cases needing high concentrations or when oral administration is impractical.
owl:sameAs
n10:DB01301 n11:DB01301
dcterms:title
Rolitetracycline
adms:identifier
n6:46507805 n7:D02282 n8:5282179 n12:PA164779049 n14:Rolitetracycline n17:4445374 n18:DB01301
n3:mechanismOfAction
Rolitetracycline is a semisynthetic broad-spectrum tetracycline antibiotic used especially for parenteral administration in cases requiring high concentrations or when oral administration is impractical. Rolitetracycline passively diffuses through porin channels in the bacterial membrane and reversibly binds to the 30S ribosomal subunit, preventing binding of tRNA to the mRNA-ribosome complex, and thus interfering with protein synthesis.
n3:synonym
Synterin Rolitetracyclinum Pyrrolidino-methyl-tetracycline Rolitetraciclina N-(1-Pyrrolidinylmethyl)-tetracycline N-(Pyrrolidinomethyl)tetracycline Reverin
n3:toxicity
Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD<sub>50</sub>=262 mg/kg (I.P. in rat).
n3:synthesisReference
Horacio Alfredo Priestap, Carlos Rappaport, "Process for producing rolitetracycline." U.S. Patent US3985768, issued September, 1963.
n3:IUPAC-Name
n4:271B6459-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B645F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B645E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B645B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B645C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B645D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B646F-363D-11E5-9242-09173F13E4C5 n4:271B6457-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6455-363D-11E5-9242-09173F13E4C5 n4:271B6458-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6456-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:J01AA09
n3:H-Bond-Acceptor-Count
n4:271B6465-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6466-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6460-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6461-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6463-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6462-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6464-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
751-97-3
n3:category
n3:Bioavailability
n4:271B646B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B646D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B646E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B646A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6469-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B646C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B645A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6467-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6468-363D-11E5-9242-09173F13E4C5